title: [Effects of OK-432 intraportal administration on cell-mediated immune responses].
abstract: The effects of OK-432 and/or MMC on host immunity were studied in patients with advanced colorectal cancer. OK-432 was administered to the portal vein, and MMC was dispersed into the peritoneal cavity for prevention of liver metastasis. In the MMC group, NK activity was significantly reduced at 7 days postoperatively, while such a reduction was not seen in the OK and OK + MMC groups. The administration of OK-432 decreased the postoperative proportion of suppressor T cells in the lymphocyte subsets more than that of MMC group. Our results strongly suggest that intraoperative administration of BRM to the patients with advanced colorectal cancer can significantly prevent postoperative immunosuppression.
authors.affiliation: 2nd Dept. of Surgery, Toyama Medical and Pharmaceutical University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Minamimura
authors.forename: S
authors.initials: S
authors.lastname: Katsuyama
authors.forename: K
authors.initials: K
authors.lastname: Yamasaki
authors.forename: H
authors.initials: H
authors.lastname: Ookami
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: K
authors.initials: K
authors.lastname: Masuyama
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Takemori
authors.forename: H
authors.initials: H
authors.lastname: Arai
authors.forename: T
authors.initials: T
authors.lastname: Sakamoto
authors.forename: K
authors.initials: K
authors.lastname: Tazawa
authors.forename: M
authors.initials: M
authors.lastname: Fujimaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy; D007263:Infusions, Parenteral; D007694:Killer Cells, Natural / Q000276:immunology; D008113:Liver Neoplasms / Q000517:prevention & control; D016131:Lymphocyte Subsets; D016685:Mitomycin / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage*
chemical_list: D007155:Immunologic Factors; D010844:Picibanil; D016685:Mitomycin